Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29215669 | 0.92 | CYP4F2 (0.40) | USP2SMN1; SMN2KDM4EPKMTSHR | |
| SCHEMBL3491874 | 0.85 | ALDH1A1 (0.44) | USP2SMN1; SMN2PKMEPHX2TSHR | |
| SCHEMBL335137 | 0.85 | TDP1 (0.46) | TSHRALDH1A1MEN1KMT2AHCRTR2 | |
| SCHEMBL1446859 | 0.84 | MEN1 (0.48) | KDM4EPKMMEN1KMT2A | |
| SCHEMBL21930398 | 0.82 | MEN1 (0.41) | TSHRALDH1A1MEN1KMT2AHCRTR2 | |
| SCHEMBL7609309 | 0.82 | MEN1 (0.41) | TSHRALDH1A1MEN1KMT2AHCRTR2 | |
| SCHEMBL7303096 | 0.81 | USP2 (0.47) | USP2SMN1; SMN2EPHX2TSHRALOX15 | |
| SCHEMBL6803134 | 0.81 | EPHX1 (0.42) | TSHRALDH1A1MEN1KMT2AHCRTR2 | |
| SCHEMBL965651 | 0.81 | USP2 (0.51) | USP2SMN1; SMN2EPHX2TSHRALOX15 | |
| SCHEMBL1978460 | 0.81 | USP2 (0.42) | USP2SMN1; SMN2KDM4EPKMEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120798-A1 | SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY | ASTEX THERAPEUTICS LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| US-20100120798-A1 | SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY | ASTEX THERAPEUTICS LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| US-20100120798-A1 | SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY | ASTEX THERAPEUTICS LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| CN-101627042-A | Substituted piperidines containing a heteroarylamide or heteroarylphenyl moiety | ASTEX THERAPEUTICS LTD | 2010-01-13 | — | — | CN | disclosed |
| EP-2125820-A1 | SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY | Astex Therapeutics Limited (GB) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008075110-A1 | SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY | ASTEX THERAPEUTICS LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008075110-A1 | SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY | ASTEX THERAPEUTICS LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120798-A1 | SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY | GRK2, GNAO1, PTGER1 | USP2 3455/4885SMN1; SMN2 3995/4885KDM4E 3386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.